Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Contribution of Contrast-Enhanced Ultrasound (CES) in the Fetal-placental Circulation Study
NCT06497959Phase 3Recruiting
- Sponsor
- CHRU de Nancy - Hôpital Central
- Start
- Apr 2025
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of sulfur hexafluoride in fetal growth restriction (FGR) (2 arms), sponsored by CHRU de Nancy - Hôpital Central. Primary endpoint: Measurement of signal strength at 1 day. Started Apr 2025; status: recruiting.
02
Drugs
sulfur hexafluoride
03
Conditions
fetal growth restriction (FGR)
Beyond the preview
Go deeper on NCT06497959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06497959.